{
    "clinical_study": {
        "@rank": "31929", 
        "arm_group": [
            {
                "arm_group_label": "Afatinib in moderate renal impaired", 
                "arm_group_type": "Experimental", 
                "description": "Single Dose Afatinib in moderate renal impaired subjects"
            }, 
            {
                "arm_group_label": "Afatinib in severe renal impaired", 
                "arm_group_type": "Experimental", 
                "description": "Single Dose Afatinib in severe renal impaired subjects"
            }, 
            {
                "arm_group_label": "Afatinib in healthy subjects", 
                "arm_group_type": "Other", 
                "description": "Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the current study is to investigate the influence of moderate to\n      severe renal impairment on the pharmacokinetics and safety of a single dose afatinib in\n      comparison to a control group with normal renal function.\n\n      The assessment of safety and tolerability will be an additional objective of this trial and\n      will be evaluated by descriptive statistics."
        }, 
        "brief_title": "Afatinib in Subjects With Kidney Dysfunction", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Insufficiency", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Despite renal impairment (group 1 and 2) healthy males or females according to the\n             investigators assessment, as based on the following criteria: a complete medical\n             history including a physical examination, vital signs (Blood Pressure (BP), Pulse\n             Rate (PR)), 12-lead Electrogardiogram (ECG), and clinical laboratory tests.\n\n          -  Glomerular filtration rate (GFR), estimated according to:\n\n             -- MDRD (Modification of Diet in Renal Disease)-formula:\n\n               -  eGFR (estimated Glomerular Filtration Rate) [ml/min/1.73m\u00b2]= 175 x Serum\n                  Creatinine-1.154 x age-0.203 (if male)\n\n               -  eGFR[ml/min/1.73m\u00b2]= 175 x Serum Creatinine-1.154 x age-0.203 x 0.742 (if\n                  female)\n\n               -  30 to 59 mL/min for moderate renal impairment group 1\n\n               -  15 to 29 mL/min for severe renal impairment group 2\n\n               -  = 90 mL/min for healthy volunteers group 3\n\n          -  Age =18 and =79 years\n\n        Exclusion criteria:\n\n          -  Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate\n             (PR) and Electrocardiogram (ECG)) deviating from normal and of clinical relevance,\n             e.g. repeated measurement of systolic blood pressure < 90 mmHg (millimeter of\n             mercury) or > 140 mmHg, diastolic blood pressure < 50 mmHg or > 90 mmHg, repeated\n             measurement of pulse rate < 45 bpm (beats per minute) or > 90 bpm.\n\n          -  Any evidence of a clinically relevant concomitant disease.\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological, dermatological or hormonal disorders.\n\n          -  Relevant gastrointestinal tract surgery (except appendectomy).\n\n          -  Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric\n             disorders or neurological disorders.\n\n          -  History of photosensitivity or recurrent rash.\n\n          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or\n             neurological disorders."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096718", 
            "org_study_id": "1200.216", 
            "secondary_id": "2013-004825-98"
        }, 
        "intervention": [
            {
                "arm_group_label": "Afatinib in healthy subjects", 
                "intervention_name": "Afatinib healthy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Afatinib in severe renal impaired", 
                "intervention_name": "Afatinib severe renally impaired", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Afatinib in moderate renal impaired", 
                "intervention_name": "Afatinib moderate renally impaired", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kiel", 
                    "country": "Germany"
                }, 
                "name": "1200.216.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Pharmacokinetics, Safety and Tolerability After Single Dose Administration of Afatinib in Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "312 hours"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "312 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096718"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
            "safety_issue": "No", 
            "time_frame": "312 hours"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}